Binah Baum is a highly experienced bio-executive skilled in the management of biopharmaceutical innovation, from startup creation through incubation funding and beyond.
Binah has nurtured more than 30 biomedical startups, delivering six exits so far (IPO and corporate deals). She has been pro-actively engaged in groundbreaking developments, many of which have left a lasting mark on the biomedical landscape. During her longstanding multinational career Binah has held top management positions with incubators and top tier VCs, including a VC fund created by the legendary venture capitalist Fred Adler, where she took part in the establishment of Israel’s biotechnology ecosystem and its first biotech startup company. She has served as expert in life sciences entrepreneurship for EU policy-making commissions, cluster organizations and bioregion-consortia following which she initiated the establishment of BioNegev, a bio-innovation hub centered around Ben-Gurion University of the Negev.
Binah obtained her PhD in Chemistry and Life-sciences from the Weizmann Institute of Science. She received postdoctoral training at the University of Pennsylvania Medical School, and her MBA in Management of Innovation from Columbia Business School.
Alain Rolland is an executive with over 30 years of international leadership experience (CEO, COO, CSO) in several Pharmaceutical (Ciba Geigy, Galderma) and Biotech companies (GENEMEDICINE, Valentis, Vical, Huya, CHIME BioTherapeutics and Emerald Health Pharmaceuticals). He has worked on the discovery and development of biologics, in particular plasmid-based therapeutics and vaccines, as well as small molecules, for a variety of therapeutic areas including immuno-oncology, cardiovascular and CNS disorders, dermatology and infectious disease vaccines. He has led multidisciplinary functions and programs, filed a number of INDs and managed several clinical development programs through international Phase 3 studies.
Dr. Rolland received a Doctorate in Pharmacy, a degree in Pharmacokinetics and Biopharmaceutics and a Ph.D. in Pharmaceutical Sciences from Rennes University (France). He has published over 90 scientific articles and book chapters, and he is the editor of three scientific books. He is a member of several scientific societies and the founding Editor-in-Chief of ‘Current Pharmaceutical Biotechnology’. He is an inventor of more than 20 international patents and the recipient of the 2008 ‘Fellowship Award’ from the American Association of Pharmaceutical Scientists.
Francisco Javier Quintana is professor of neurology at the Ann Romney Center for Neurologic Diseases, at Brigham and Women’s Hospital, Harvard Medical School, and an associate member at the Broad Institute of Harvard and MIT.
Prof. Quintana is the incoming President of the International Society of Neuro Immunology (ISNI)
Prof. Quintana is a world authority on immune regulation and Tolerance. The Quintana lab is focused on the characterization of signaling pathways that control the activity of the immune system, with the ultimate goal of identifying novel therapeutic targets and biomarkers for immune-mediated disorders.
.Prof. Quintana obtained his PhD in immunology at the Weizmann Institute of Science. He received postdoctoral training at the Weizmann Institute of Science and Harvard Medical School. In 2009, Dr. Quintana joined the faculty of Harvard Medical School. He is the recipient of the Lady Anne Chain Prize for Academic Excellence and Scientific Achievements, the Junior Investigator Award from the National Multiple Sclerosis Society, the Pathway to Independence Award of the National Institute of Allergy and Infectious Diseases, the Award for Outstanding Research Achievement from Nature Biotechnology, the Tecan Award for Innovation, the Harry Weaver Award from the National Multiple Sclerosis Society, the Mentor Award from Harvard Medical School, the Milestones in Multiple Sclerosis Research Award from the National Multiple Sclerosis Society, the American Association of Immunologists-BD Biosciences Investigator Award and the Barancik Prize of Innovation in Multiple Sclerosis Research.